Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 90.8%

Neg 0% Neu 0% Pos 90.8%

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $24 to $30.